Zura Bio LTD 8-K filings

Zura Bio Limited will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025.

Zura Bio highlights its pipeline of dual-pathway biologics, ongoing clinical trials, and financial strength to support operations through 2027.

Zura Bio has launched a global Phase 2 clinical trial, named TibuSURE, to evaluate the effectiveness of tibulizumab in treating adults with systemic sclerosis.

Zura Bio Limited will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, and host investor meetings in New York.

Zura Bio has submitted a protocol to the FDA for a Phase 2 clinical trial of tibulizumab, a dual-pathway antibody, for the treatment of systemic sclerosis.

Zura Bio announced its third quarter 2024 financial results, highlighting progress in clinical trials and a strong cash position.

Zura Bio will participate in two investor conferences in November to engage with investors and discuss their clinical-stage immunology pipeline.

Zura Bio Limited held its Annual General Meeting on October 23, 2024, where shareholders elected nine directors and ratified the appointment of its independent auditor.

Zura Bio Limited has announced the departure of its Chief Scientific Officer, Michael Howell, effective October 15, 2024.

Zura Bio has released an updated corporate presentation detailing its clinical pipeline, strategic milestones, and financial position, including a cash runway through 2027.

Zura Bio will present at three investor conferences in September to discuss their clinical-stage immunology pipeline.

Zura Bio Limited has entered into an agreement with Venrock Healthcare Capital Partners, resulting in the surrender of 4 million shares and the issuance of new pre-funded warrants.

Zura Bio has released an updated corporate presentation detailing its pipeline of dual-pathway biologics and upcoming clinical milestones.

Zura Bio reported its second quarter 2024 financial results, highlighted by progress in clinical programs and a strengthened management team.

Zura Bio has successfully completed its exchange offer for outstanding warrants and will mandatorily exchange all remaining warrants for Class A ordinary shares.

Zura Bio successfully completed its exchange offer and consent solicitation for its outstanding warrants, with a high participation rate from warrant holders.

Zura Bio Limited has reached a settlement agreement with former CEO Someit Sidhu, finalizing his departure and outlining compensation and stock option vesting.

Zura Bio is offering to exchange outstanding warrants for Class A ordinary shares and seeking consent to amend the warrant agreement to reduce potential dilution.

Zura Bio has formalized the transition of its CEO from Someit Sidhu to Robert Lisicki, along with adjustments to Mr. Lisicki's compensation package.

Zura Bio shared positive Phase 1 and preclinical data for tibulizumab (ZB-106), demonstrating its potential in treating Sjogrens syndrome and rheumatoid arthritis through dual inhibition of IL-17A and BAFF.

Zura Bio has established a Scientific Advisory Board (SAB) comprising leading specialists in rheumatology, dermatology, and immunology to guide its clinical development programs.

Zura Bio announced it will present pre-clinical data at EULAR 2024, exploring the potential of its dual-pathway antibody, tibulizumab (ZB-106), in Sjogren's syndrome and rheumatoid arthritis.

Zura Bio Limited will participate in two investor conferences in June, presenting their clinical-stage immunology programs.

Zura Bio announced its first quarter 2024 financial results, highlighted by a successful $112.5 million private placement and key leadership appointments, extending its cash runway through 2027.

Zura Bio has successfully raised $112.5 million through a private placement to fund the development of its dual-pathway antibody therapies.

Zura Bio has announced the appointment of Robert Lisicki as its new CEO and Director, succeeding Dr. Someit Sidhu, who will remain on the board.

Zura Bio reported its full year 2023 financial results, highlighted by a successful Nasdaq listing and the appointment of Robert Lisicki as the new CEO, effective April 8, 2024.

Zura Bio presented its strategic vision, clinical pipeline, and key objectives to banks and analysts, highlighting its focus on immunology and novel bi-specific antibody treatments.

Zura Bio's senior management will participate in three conferences in March to present company updates and engage with investors and industry partners.

Zura Bio Limited has engaged WithumSmith+Brown as its new independent auditor, replacing Marcum LLP, following the completion of a business combination.